Comparative potency

Xydalba has a similar spectrum of in vitro activity to the other glycopeptides, but it is more potent than vancomycin or teicoplanin15.

dalbavancin in vitro activity against S. aureus16

MRSA (N=19,721)

MRSA = Methicillin-resistant Staphylococcus aureus

MSSA (N=27,052)

MSSA = Methicillin-susceptible Staphylococcus aureus

dalbavancin in vitro activity vs. older glycopeptides against S. aureus17

Graph showing dalbavancin in vitro activity vs. older glycopeptides against S. aureus
Global collection of 46,773 S. aureus isolates from 210 medical centres in 33 countries (4 continents) in 2002 – 2007
15 Malabarba A & Goldstein BP. J Antimicrob Chemother. 2005;55 Suppl 2:ii15-20
16 Biedenbach DJ, et al. Antimicrob Agents Chemother. 2009;53(3):1260-3
17 Biedenbach DJ & Jones RN. Diagn Microbiol Infect Dis. 2009;64(2):177-84